In 2017, Britain’s biggest pharmaceutical company GlaxoSmithKline (GSK) confirmed its commitment to invest £540 million in the PainPod arena of electroceuticals – also known as bioelectronics.
To develop a device that, just like PainPod, alters the electrical impulses in the body.
This device will be implantable within the human body via keyhole surgery. Kris Famm, who heads up the venture, predicts a ‘brave new future’ with bioelectronics becoming a mainstay of medical treatment over the next two decades. Kris says this will benefit up to 2 billion people – a quarter of the global population – who are suffering from chronic diseases including arthritis and diabetes*.
PainPod is watching this development with excitement. In the meantime, PainPod 3 spearheads the electroceutical non-invasive market as the world’s most advanced physical therapy device.
* theguardian.com August 2017